U.S. Markets closed

NPS Pharmaceuticals price target raised to $35 from $25 at Leerink

Leerink raised its price target for NPS Pharmaceuticals citing increased confidence on the commercial potential of Natpara for the treatment of hypoparathyroidism. The firm calls NPS a top pick for the second half of 2013 and reiterates an Outperform rating on the stock.